Abbott, Merck Like FDA's Plan To Amass More Summary Adverse Event Reports, But P&G Says There's A Better Way

While mammoth manufacturers Abbott Laboratories and Merck & Co. – along with device industry advocacy groups – are supporting the US agency's proposed Voluntary Malfunction Summary Reporting Program, Procter & Gamble Co. is urging FDA to think twice. In comments to the agency, P&G's principal scientist says the program, which will allow firms to submit Medical Device Reports to FDA quarterly in a bundled format for a wide array of products, should be scrapped and replaced with an 11-year-old congressional mandate that aimed to boost summary reports.

bundles bales of paper documents. stacks packs pile on the desk in the office

Mammoth manufacturers Abbott Laboratories Inc. and Merck & Co. Inc., along with some device industry advocacy groups, are cheering on US FDA's plan to collect more adverse events in a summarized format. But one device-maker – Procter & Gamble Co. – is urging the agency to rethink its plan.

Proposed by FDA in December, the Voluntary Malfunction Summary Reporting Program will allow companies to submit Medical Device Reports to the agency each quarter in a bundled, line-item fashion for a wide array of products

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation